Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Gastrointestinal Stromal Tumors 71Leukemia 69Leukemia, Myeloid, Chronic-Phase 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 43Blast Crisis 22Neoplasms 15Brain Neoplasms 15Philadelphia Chromosome 14Melanoma 13Sarcoma 12Neoplasm Metastasis 12Leukemia, Myeloid, Acute 12Leukemia, Myeloid, Accelerated Phase 12Glioblastoma 12Lung Neoplasms 11Prostatic Neoplasms 10Leukemia, Myeloid 9Gliosarcoma 9Glioma 8Breast Neoplasms 8Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Central Nervous System Neoplasms 7Astrocytoma 7Recurrence 6Polycythemia Vera 6Ovarian Neoplasms 6Oligodendroglioma 6Myeloproliferative Disorders 6

Interventions

Oxaliplatin 6Irinotecan 5Fluorouracil 5Drug Therapy 4Bevacizumab 4Magnetic Resonance Spectroscopy 3Leucovorin 3Capecitabine 35,10-methylenetetrahydrofolic acid 3pembrolizumab 2Ocoxin 2Levoleucovorin 2Folfox protocol 2Exercise Test 2Cyclophosphamide 2Cetuximab 2trifluridine tipiracil drug combination 1sintilimab 1repotrectinib 1pralsetinib 1penpulimab 1napabucasin 1lutetium Lu 177 dotatate 1huachansu 1guadecitabine 1golotimod 1encorafenib 1copper dotatate CU-64 1alectinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Diseases × Imatinib Mesylate × Clear all
NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
91 enrolled 11 charts
GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡